Open AccessEffectiveness and safety of adalimumab biosimilar ABP 501 in Crohn�s disease: an observational study
Author(s) -
Davide Giuseppe Ribaldone,
Gian Paolo Caviglia,
Rinaldo Pellicano,
Marta Vernero,
Giorgio Maria Saracco,
Mario Morino,
Marco Astegiano
Publication year - 2020
Publication title -
revista española de enfermedades digestivas/revista española de enfermedades digestivas
Language(s) - English
Resource type - Journals
eISSN - 2340-4167
pISSN - 1130-0108
DOI - 10.17235/reed.2020.6693/2019
Subject(s) - medicine , adalimumab , biosimilar , crohn's disease , observational study , adverse effect , regimen , disease , gastroenterology , surgery
there are no studies in the literature about the effectiveness of adalimumab biosimilar ABP 501 in Crohn's disease. The aim of this study was to evaluate its effectiveness and safety.